Eton Pharmaceuticals Management

How has Sean Brynjelsen's remuneration changed compared to Eton Pharmaceuticals's earnings?
Date	Total Comp.	Salary	Company Earnings
Mar 31 2023	n/a	n/a	-US$6m
Dec 31 2022	US$2m	US$570k	-US$9m
Sep 30 2022	n/a	n/a	-US$9m
Jun 30 2022	n/a	n/a	-US$12m
Mar 31 2022	n/a	n/a	-US$12m
Dec 31 2021	US$2m	US$542k	-US$2m
Sep 30 2021	n/a	n/a	-US$11m
Jun 30 2021	n/a	n/a	-US$11m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$2m	US$476k	-US$28m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$21m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	US$2m	US$410k	-US$18m
Sep 30 2019	n/a	n/a	-US$42m
Jun 30 2019	n/a	n/a	-US$40m
Mar 31 2019	n/a	n/a	-US$41m
Dec 31 2018	US$493k	US$332k	-US$37m
Sep 30 2018	n/a	n/a	-US$18m
Dec 31 2017	US$654k	US$172k	-US$13m

Compensation vs Market: Sean's total compensation ($USD2.12M) is above average for companies of similar size in the US market ($USD756.65K).

Compensation vs Earnings: Sean's compensation has increased whilst the company is unprofitable.

CEO

Sean Brynjelsen (51 yo)

6yrs

Tenure

US$2,119,541

Compensation

Mr. Sean E. Brynjelsen has been the Chief Executive Officer at Eton Pharmaceuticals, Inc. since June 23, 2017 and serves as President and Director since June 2017. Mr. Brynjelsen served as Executive Vice P...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sean Brynjelsen	President	6yrs	US$2.12m	4.21% $ 4.3m
James Gruber	CFO, Treasurer & Secretary	1.2yrs	US$810.88k	0.014% $ 14.3k
David Krempa	Chief Business Officer	less than a year	no data	0.032% $ 32.4k
Ingrid Hoos	Senior Vice President of Regulatory Affairs	2.8yrs	no data	no data
Kevin Guthrie	Executive VP of Commercial Operations	1.4yrs	no data	no data

1.4yrs

Average Tenure

51yo

Average Age

Experienced Management: ETON's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sean Brynjelsen	President	6yrs	US$2.12m	4.21% $ 4.3m
Paul Maier	Independent Director	5.8yrs	US$185.85k	0.23% $ 236.6k
Charles Casamento	Independent Director	6yrs	US$183.35k	0.27% $ 270.9k
Norbert Riedel	Independent Chairman	5.8yrs	US$210.85k	0.23% $ 236.6k
Jennifer Adams	Independent Director	2.3yrs	US$175.85k	no data

5.8yrs

Average Tenure

65yo

Average Age

Experienced Board: ETON's board of directors are considered experienced (5.8 years average tenure).

Eton Pharmaceuticals Management

Management criteria checks 1/4

Key information

Recent management updates

Eton Pharmaceuticals, Inc. Appoints James Gruber as Chief Financial Officer

Director has left the company

Eton Pharmaceuticals, Inc. Announces Board Changes

Recent updates

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Eton Pharmaceuticals, Inc. Announces Commercial Availability of Betaine Anhydrous for Oral Solution, A Generic Version of Cystadane® (Betaine Anhydrous for Oral Solutions)

Eton Pharmaceuticals, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection

Consensus estimates of losses per share improve by 14%

Eton Pharmaceuticals, Inc Submits New Drug Application Response for Its Dehydrated Alcohol Injection Product Candidate to the U.S. Food and Drug Administration

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Debt In A Risky Way?

Forecast to breakeven in 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Eton Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 10, 2022

Eton Pharmaceuticals acquires FDA-approved rare disease product betaine anhydrous

Eton Pharmaceuticals: An Evolving 'Sum Of The Parts' Story

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Eton Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Price target decreased to US$9.00

Eton Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Approves ZONISADE

Eton Pharma jumps 20% on FDA approval of seizure therapy

Eton Pharmaceuticals, Inc. Provides Revenue Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Eton Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 12, 2022

Price target decreased to US$10.50

Broker Revenue Forecasts For Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Are Surging Higher

Consensus forecasts updated

Eton Pharmaceuticals, Inc. Appoints James Gruber as Chief Financial Officer

Consensus revenue estimates increase by 11%

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$10.00

Eton Pharmaceuticals Receives Notice from the Zonisamide Oral Suspension Product Candidate That the United States Food and Drug Administration (“Fda”) Has Scheduled an On-Site Inspection of the Facility Beginning

Eton Pharmaceuticals, Inc and ANI Pharmaceuticals, Inc Announce Commercial Availability of Carglumic Acid Tablets

Third quarter 2021 earnings released: US$0.24 loss per share (vs US$0.31 loss in 3Q 2020)

Eton Pharmaceuticals (NASDAQ:ETON) Is Using Debt Safely

Another Look At Eton Pharmaceuticals

Price target increased to US$14.00

Second quarter 2021 earnings released: US$0.08 loss per share (vs US$0.23 loss in 2Q 2020)

What Does The Future Hold For Eton Pharmaceuticals, Inc. (NASDAQ:ETON)? These Analysts Have Been Cutting Their Estimates

Eton Pharmaceuticals, Inc.(NasdaqGM:ETON) dropped from Russell 3000E Index

Eton Pharmaceuticals, Inc Acquires U.S. and Canadian Rights to Crossject's ZENEO Hydrocortisone Needleless Autoinjector

Eton Pharma wins FDA approval for Rezipres

Eton Pharmaceuticals, Inc Receives Complete Response Letter from U.S. FDA for Dehydrated Alcohol Injection

Price target decreased to US$12.50

FDA declines to approve Eton Pharmaceuticals' methanol poisoning treatment

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Is About To Turn The Corner

First quarter 2021 earnings released: EPS US$0.21 (vs US$0.50 loss in 1Q 2020)

Is Eton Pharmaceuticals (NASDAQ:ETON) Using Too Much Debt?

Director has left the company

Eton Pharmaceuticals, Inc. Announces Board Changes

Eton Pharmaceuticals, Inc. to Report Q4, 2020 Results on Mar 16, 2021

New 90-day low: US$7.72

Could The Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Ownership Structure Tell Us Something Useful?

Eton Pharmaceuticals Announces Marketing Agreement with Bausch Health to Launch of Alaway Preservative Free

New 90-day high: US$9.88

New 90-day high: US$9.12

Diurnal Group plc Announces It Has Extended Its Exclusive Licence Arrangement for Alkindi with Eton Pharmaceuticals, Inc

Eton Pharma buys Canadian rights for Alkindi Sprinkle

Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Shift From Loss To Profit

Price target lowered to US$14.00

Analysts lower revenue estimates to US$1.16m

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Topiramate Oral Solution

FDA accepts Eton application for Topiramate for partial seizures

Eton Pharmaceuticals, Inc Announces Availability of Orphan Drug ALKINDI® SPRINKLE (hydrocortisone) in the United States

Eton Pharmaceuticals announces availability of ALKINDI SPRINKLE in U.S.

Analysts increase revenue estimates to US$4.84m

Price target raised to US$16.50

Earnings beat expectations, revenue disappoints

Eton Pharmaceuticals, Inc. to Report Q3, 2020 Results on Nov 12, 2020

Eton Pharmaceuticals Announces Acceptance for Filing of New Drug Application for Zonisamide Oral Suspension

Eton Pharmaceuticals, Inc. Announces Acceptance for Filing of New Drug Application for Orphan Drug Dehydrated Alcohol Injection

Eton Pharmaceuticals, Inc. and Tulex Pharmaceuticals Submit New Drug Application for Topiramate Oral Solution

Analysts update estimates

Price target raised to US$16.00

Eton Pharmaceuticals Announces FDA Approval of Alkindi Sprinkle as Replacement Therapy in Pediatric Patients with Adrenocortical Insufficiency